Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
ASSERTIO THERAPEUTICS INC

ASRT-OLD2

ASSERTIO THERAPEUTICS INC

ASSERTIO THERAPEUTICS INC historical holders

total: 1

Oaktree Capital Management ASSERTIO THERAPEUTICS INC transactions over time

Total transactions:
2
New positions:
1
Sold out:
1
Held since:
2019 Q3
Held for:
3 quarters
Latest activity:
2020 Q2
Howard Marks has been an institutional investor in ASSERTIO THERAPEUTICS INC (ASRT-OLD2) since 2019 Q3. According to 2026 Q1 report, Howard Marks doesn't hold any shares. The fund/company first acquired ASRT-OLD2 in 2019 Q3, initially purchasing about 1.49M shares. Since the initial investment, Oaktree Capital Management has made 1 more transaction in this position.

When did Howard Marks exit their ASRT-OLD2 position?

Howard Marks no longer holds ASSERTIO THERAPEUTICS INC (ASRT-OLD2). They sold off their entire position in 2020 Q2, closing out an investment that began in 2019 Q3.

When did Howard Marks first invest in ASRT-OLD2?

Howard Marks first invested in ASSERTIO THERAPEUTICS INC (ASRT-OLD2) in 2019 Q3 at the reported quarter-end price of $1.28 per share, acquiring 1,492,455 shares in their initial purchase.

What is Howard Marks's average cost basis for ASRT-OLD2?

Based on historical transaction data, Howard Marks's estimated cost basis for ASSERTIO THERAPEUTICS INC (ASRT-OLD2) is approximately $1.28 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$1.28
Weighted AVG sell price:
$0.65

ASRT-OLD2 transactions history by Oaktree Capital Management

2 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2020 Q2
0.00%
$0.65
-100% (-1,492,455)
2019 Q3
0.04%
$1.28
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.